医学
坏死性小肠结肠炎
婴儿配方奶粉
巴氏杀菌
母乳喂养
早产儿视网膜病变
母乳
败血症
重症监护医学
免疫学
儿科
食品科学
怀孕
生物
胎龄
生物化学
遗传学
作者
Christine Schreiner,Andreas Müller,Till Dresbach
出处
期刊:Breastfeeding Medicine
[Mary Ann Liebert]
日期:2023-11-16
卷期号:18 (12): 901-907
被引量:1
标识
DOI:10.1089/bfm.2023.0155
摘要
Mother's own milk is recognized as the optimal feeding not only for term but also for preterm infants. In addition to risk reduction for sepsis, necrotizing enterocolitis, bronchopulmonary dysplasia, and retinopathy of prematurity in the early infancy, feeding preterm infants with mother's own milk is also associated with a better neurodevelopmental outcome; lower rates of otitis media, gastroenteritis, and respiratory infections; and a reduced risk of cardiovascular disease, obesity, and diabetes later in life. Donor human milk is the best alternative if mother's own milk is not available or with short supply. There is growing evidence that the benefits of human milk are mediated by the human milk microbiota and by human milk oligosaccharides through their influence on the infant's gut microbiota. Unfortunately, although human milk contains beneficial bacteria, it may also contain pathogenic bacteria. The antimicrobial properties of human milk protect those infants fed with their own mother's raw milk. In donor human milk, however, the antimicrobial activity is diminished due to storage and in particular by pasteurization, hereby lowering the resistance against bacterial infections. Subsequently, microbiological screening of donor human milk might enhance its safety for preterm infants. Up to date, a consensus on recommendations for the microbiological testing of donor human milk is lacking. Existing local and national guidelines for the microbiological screening vary significantly in terms of timing and frequency of testing as well as their specific acceptance and discard criteria. We reviewed the literature about microbiological testing of donor human milk to provide evidence-based recommendations for donor human milk.
科研通智能强力驱动
Strongly Powered by AbleSci AI